細胞動力 CYTK 深 滬
等待開盤 07-26 09:30:00 美东时间
37.18
-0.130
-0.35%
華盛通- 最 高38.165
- 今 開37.43
- 成交量 100.91万股
- 最 低 36.70
- 昨 收 37.31
- 總市值 44.24亿
- 52周最高 59.39
- 市盈率 靜 --
- 換手率 0.85%
- 52周最低 29.31
- 委 比 75.77%
- 總股本 1.19亿
- 歷史最高 110.25
- 量 比 0.90
- 振 幅 3.93%
- 歷史最低 0.57
- 每 手 1
- 風險率 15.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cytokinetics to Announce Second Quarter Results On August 7, 2025
Cytokinetics scheduled to report Q2 results on Aug 7 at 4:00 PM ET, followed by a conference call at 4:30 PM ET to discuss financials and updates. The call will be webcast on their website, with a replay available for six months. Cytokinetics is a cardiovascular biopharmaceutical company advancing potential new medicines for cardiac muscle dysfunction, preparing for regulatory approvals of aficamten, a cardiac myosin inhibitor, and developing oth...
07-24 20:00
Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025
Cytek Biosciences announced it will release its Q2 2025 financial results after market close on August 6, 2025. Management will host a webcast conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results, business developments, and outlook. A live audio webcast will be available on the company’s Investor Relations website. Cytek Biosciences is a leading provider of advanced cell analysis solutions, leveraging its patented Full Spectrum Profi...
07-23 20:05
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
Cytokinetics公司宣布其药物aficamten在欧洲心脏病学会大会上将展示五个相关报告，其中包括MAPLE-HCM试验的阳性顶线结果，以及在三项临床试验中房颤的发病率和影响。这些研究展示了aficamten在梗阻性肥厚型心肌病患者中的疗效和安全性。公司正准备基于阳性结果寻求aficamten的监管批准，并继续扩展其治疗心肌病和心力衰竭的管线。
07-10 11:30
Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds
Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch.
06-25 02:35
12款小分子新药化学结构首次公开
转自：中国医药报 在前不久美国化学会（ACS）举行的2025春季会议上，12款已进入或即将进入临床试验的小分子药物的化学结构首次公开亮相，这些潜在的新药适应证...
06-19 08:18
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics granted stock options for 83,583 shares and 56,334 RSUs to 11 new employees as employment inducements. The RSUs vest over 3 years, with 40% upon the first anniversary, 40% on the second, and 20% on the third. The stock options vest over 4 years, with 1/4 on the first anniversary and the remainder monthly over 36 months. The exercise price is $34.38 per share, matching the June 13, 2025 closing price, and the options expire in 10 year...
06-17 20:00
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program
Cytokinetics announced its annual Corporate Giving Program to support non-profits focused on equitable healthcare for cardiovascular diseases, diversity in science education, and essential services for at-risk communities in the San Francisco Bay Area and Greater Philadelphia. Applications are accepted until August 4, 2025, via cybergrants.com. The company emphasizes partnerships with non-profits to address its corporate priorities, including hea...
06-10 11:30
美股大行评级 | eToro Group获多家大行首予买入评级，甲骨文获多家机构上调目标价
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139116149842006017.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持PolyPid(PYPD)"买入"评级，目标价从11美元升至13美元</p> <p>• HC Wainwright & Co.：维持Vertical Aerosp
06-10 09:45
JP Morgan Maintains Overweight on Cytokinetics, Lowers Price Target to $53
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and lowers the price target from $71 to $53.
06-09 23:41
期权扫描 | Meta期权成交放量至60万张！Applied Digital遭PUT大单押注股价回落
Meta期权成交放量至60万张，周内股价大涨6%，公司布局军用AI头显设备；Applied Digital再飙涨29%，遭PUT大单押注股价回落>>
06-05 18:53
